17 nov: Aktier/åbning: Lundbeck og Rockwool i fokus i rødt marked
17 nov: Rockwool leverede lavere omsætning men bedre resultat end ventet
17-11-2016 09:26:42

Zealand increases its share capital as a consequence of exercise of employee warrants

Relateret indhold
16 jan - 
Bioporto vil have Zealand Pharma-topchef ind i bestyrel..
03 jan - 
Zealand Pharma: Storinvestor køber yderligere op
07 dec - 
Torsdagens aktier: Vestas vandt en suveræn førsteplads ..
Relateret debat
21 jan - 
Det bliver en god uge 😉
21 jan - 
Sidste uge sluttede med at der efter US lukke tid kom a..
20 jan - 
" Nye toner fra Baronen, som ellers aldrig fejler.. " &..

Company announcement - No. 45 / 2016

Zealand increases its share capital as a consequence of exercise of employee warrants

Copenhagen, 17 November 2016 - Zealand Pharma ("Zealand") has increased its share capital with nominal DKK 8,200 divided into 8,200 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand's employee warrant programs.

Employee warrant programs are part of Zealand's incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand share at a pre-specified price, the exercise price, in specific pre-defined time periods before expiration. For further description of Zealand's warrant programs, see the company's Articles of Association, which are available on the homepage: www.zealandpharma.com.

The exercise price is DKK 77 per share and the total proceeds to Zealand from the capital increase amounts to DKK 631,400.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand's general meetings. Zealand only has one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 26,070,453 divided into 26,070,453 shares with a nominal value of DKK 1 each.

The amendment of Zealand's Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority.

*****

For further information, please contact:

Mats Blom,

Senior Vice President, Chief Financial Officer

Tel: +45 31 53 79 73, email:mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn and a pipeline of proprietary product candidates, which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analog for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as AdlyxinTM in the United States. Lixisenatide has been developed in a fixed-ratio combination with Lantus® (insulin glargine) which product is under regulatory review in the United States and in Europe. 

Zealand's proprietary pipeline includes: Dasiglucagon* (ZP4207) as single-dose rescue treatment for acute, severe hypoglycemia (Phase II); Glepaglutide* (ZP1848) for treatment of short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN)

45-16_1117 Warrant exercise and capital increase


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 771002.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
20 jan
ZEAL
Godt at se at de kan hoppe direkte i fase 3 og ikke skal køre kombineret fase 2-3 studie. Det betyde..
6
19 jan
ZEAL
Published: 23:30 CET 19-01-2018 /GlobeNewswire /Source: Zealand Pharma / : ZEAL /ISIN: DK0060257814 ..
5
15 jan
ZEAL
I den norske udgave af Dagens Medicin er en interssant artikel (se nedenfor). Artiklen diskuterer at..
5
21 jan
ZEAL
Sidste uge sluttede med at der efter US lukke tid kom accept fra FDA til direkte at gå i fase 3 med ..
4
15 jan
ZEAL
MÆGLERSTATISTIK   MæglerKøbtSolgtNettoInternt Største købere Goldman Sachs International 1..
4
20 jan
ZEAL
"Måske tager jeg fejl"... Nye toner fra Baronen, som ellers aldrig fejler.. Det lover godt for frem..
2
19 jan
ZEAL
Zealand Pharma får direktør for udvikling på ny chefstol09:21Zealand Pharma har styrket sin direktio..
2
20 jan
ZEAL
"Nye toner fra Baronen, som ellers aldrig fejler.. "   Det var nok en fejl.   ;)
1
20 jan
ZEAL
Følg med i USA. Det bliver blødrødt og zealans vil til en vis grad blive påvirket af det. Nyhederne ..
1
20 jan
ZEAL
Super positivt - en af de gode nyheder jeg forventer i 2018 fra ellers hårdprøvede Zealand. De komm..
1

Novo Nordisk/Goldman: Diabetestablet vil få den høje vækst tilbage

19-01-2018 15:11:36
Novo Nordisk står med et meget stærkt kort på hånden, hvis selskabet får en tabletudgave af det store væksthåb Ozempic (Semaglutid) godkendt og sendt på markedet.Det mener den amerikanske investeringsbank Goldman Sachs, der vurderer, at investorerne på aktiemarkedet ikke har taget tilstrækkeligt højde for de store muligheder for diabetesmidlet.Derfor har banken hævet sit kursmål for Novo Nordisk-a..

WDH/SEB: Amerikansk høreapparatmarked vokser mere end ventet

19-01-2018 14:35:39
Der var mere fart på den private del af det amerikanske høreapparatmarked i slutningen af 2017, end den svenske bank SEB havde ventet.Det skriver Bloomberg News på baggrund af en analyse fra SEB.Den private del af det amerikanske høreapparatmarked voksede 7,3 pct. i fjerde kvartal mod 2,8 pct. i tredje kvartal ifølge tal fra American Hearing Aid Association. Det var højere, end SEB har ventet, og ..

Aktier/åbning: Børshuse skubber Chr. Hansen og Novo til tops

19-01-2018 09:23:02
Chr. Hansen og Novo Nordisk er strøget til tops på det danske aktiemarked og medvirker til at hive det danske C25-indeks i et solidt plus fredag morgen.Stemningen var ellers svagt negativ i futuremarkedet indtil kort før åbningen.C25-indekset stiger 0,5 pct. til 1160,09 og ligger til et samlet plus på 0,8 pct. i denne uge.Især Chr. Hansen er sprunget i vejret fra åbningen. Aktien stiger 3,9 pct. t..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Zealand Pharma A/S 90,20 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. januar 2018 05:21:49
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180112.1 - EUROWEB1 - 2018-01-22 05:21:49 - 2018-01-22 05:21:49 - 1 - Website: OKAY